Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 4366-4370, July 15, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gombar, C. T.
Right arrow Articles by Burak, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gombar, C. T.
Right arrow Articles by Burak, E. S.

Interspecies Scaling of the Pharmacokinetics of N-Nitrosodimethylamine1

Charles T. Gombar2, George W. Harrington, Harry M. Pylypiw, Jr., Lucy M. Anderson, Amos E. Palmer3, Jerry M. Rice, Peter N. Magee and Eric S. Burak

Department of Drug Metabolism, Smith Kline & French Laboratories, King of Prussia, Pennsylvania 19406-0939 [C. T. G., E. S. B.]; Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19140 [C. T. G., G. W. H., H. M. P., E. S. B.]; Laboratory of Comparative Carcinogenesis, National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland 21707 [L. M. A., A. E. P., J. M. R.]; and Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 [P. N. M.]

The pharmacokinetics of N-nitrosodimethylamine was studied in patas monkeys following i.v. doses of 0.5, 1.0, and 5.0 mg/kg and a p.o. dose 1.0 mg/kg, and in Swiss mice at i.v. doses of 1.0 and 2.0 mg/kg. In the patas monkey the pharmacokinetics was linear over the i.v. dose range studied. The mean clearance (Cl), steady-state volume of distribution (Vss), mean residence time, and elimination half-life (t1/2) were 103.3 ± 26.7 (SD) ml/min, 3061 ± 821 ml, 30.8 ± 10.8 min, and 21.1 ± 8.5 min, respectively. Assuming that the pharmacokinetics was linear at the p.o. dose used, the p.o. bioavailability of N-nitrosodimethylamine in the monkey was 49%. The pharmacokinetics was also linear in mice, and the average Cl,Vss, mean residence time, and t1/2 were 3.81 ml/min, 21.0 ml, 5.5 min, and 11.9 min, respectively. These data and data for rats, hamsters, rabbits, dogs, and pigs taken from the literature were used to scale Cl and Vss to body weight using the allometric equation. The resulting equation for Cl was Cl = 49.7B0.998 and the equation for Vss was Vss = 748B1.05 where B is body weight in kg. The fit of the data to the equation was excellent in both cases. Using these equations and assuming a body weight of 70 kg for humans, the Cl and Vss for N-nitrosodimethylamine in humans are estimated to be 3450 ml/min and 64,800 ml, respectively.

1 This study was supported in part by USPHS Grant CA43342 by the National Cancer Institute, Department of Health and Human Services.

2 To whom requests for reprints should be sent.

3 Deceased.

Received 12/ 7/89. Revised 3/26/90.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.